Verrica Pharma Announces Settlement Of Litigation With Dormer Labs - Quick Facts

(RTTNews) - Verrica Pharmaceuticals (VRCA) announced the settlement of litigation with Dormer Laboratories. As part of the settlement, Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States, including Dormer brands Cantharone and Cantharone Plus.

Ted White, Verrica's CEO, said: "We are pleased to announce the expeditious settlement with Dormer Labs, which Verrica believes was the largest supplier of non-FDA approved cantharidin-containing products into the U.S. market. We believe that this settlement will result in greater patient usage of the FDA-approved YCANTH."

For More Such Health News, visit rttnews.com.